Parkwood LLC Purchases New Stake in Danaher Co. (NYSE:DHR)

Parkwood LLC purchased a new position in shares of Danaher Co. (NYSE:DHR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 45,856 shares of the conglomerate's stock, valued at approximately $10,526,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Heck Capital Advisors LLC purchased a new position in shares of Danaher in the 4th quarter valued at $27,000. Decker Retirement Planning Inc. purchased a new position in shares of Danaher in the 4th quarter valued at $31,000. Golden State Wealth Management LLC purchased a new position in shares of Danaher in the 4th quarter valued at $31,000. Strategic Financial Concepts LLC purchased a new position in shares of Danaher in the 4th quarter valued at $31,000. Finally, Pineridge Advisors LLC increased its holdings in shares of Danaher by 63.3% in the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate's stock valued at $34,000 after acquiring an additional 57 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman now owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by insiders.

Danaher Stock Performance

Shares of DHR stock traded up $5.08 on Friday, hitting $196.03. The company had a trading volume of 3,868,501 shares, compared to its average volume of 3,453,040. The firm has a market cap of $140.29 billion, a P/E ratio of 37.13, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80. Danaher Co. has a twelve month low of $171.00 and a twelve month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average price of $196.87 and a 200-day moving average price of $217.64.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. As a group, equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.65%. Danaher's payout ratio is 24.85%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on DHR shares. Guggenheim reiterated a "buy" rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. JPMorgan Chase & Co. dropped their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 22nd. Royal Bank of Canada restated an "outperform" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Raymond James restated a "market perform" rating on shares of Danaher in a research note on Monday, February 3rd. Finally, Robert W. Baird dropped their target price on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Danaher has an average rating of "Moderate Buy" and an average price target of $264.40.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.